Ulcerative Colitis (UC) Clinical Trial
Official title:
An Open Label Non Randomized Pilot Study: Use of the Ulcerative Colitis Diet for Induction of Remission.
The goal of the study is to evaluate the use of Ulcerative Colitis Diet for Induction of Remission. The investigators have postulated that we developed could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
Background:
Recent research has shown that dietary components may lead to impaired intestinal innate
immunity due to alterations in the microbiome, mucous layer, intestinal permeability or
change in bacterial adherence and translocation. Pfeffer Gik et al (Dig Dis, 2014) compiled
a list of food components and additives that impair the intestinal epitheliums ability to
contain bacteria to the lumen, and consequently increase intestinal permeability which, in
turn, increases the uptake of luminal antigens and microbial factors. The list includes
Gliadin, Saturated fat milks, emulsifiers such as Carboxymethylcellulose, Polysorbate 80 and
Sodium Caprate )Levine A, Wine E, 2013). In Crohn's disease, intervention with EEN or a
Crohn's disease exclusion diet have shown high rates of remission in mild- moderate CD
patients. The CDED led to remission in 70% of patients, primarily with patients with early
mild to moderate disease (Sigall-Boneh R et al, 2014).
Unlike CD, none of these studies have systematically examined the relationship between
normal diet intake and relapses in UC. Devotka et al demonstrated that a bloom in sulphide
reducing bacteria increased colitis in IL10-/- mice. This was due to increased Bilophila
Wadsworthia which is sulphide dependent (Brown k et al, 2012). Studies have shown that the
rate of butyrate utilization in normal specimens was almost double than that found in UC
Specimens. Moreover, high fiber diet can affect the microbial composition (Pitcher MCL et
al, Gut, 2000) and regulatory T cells in the colon (Singh N et al, 2014).
Until recently, UC was not considered to be a bacteria mediated disease. However, our
increased understanding of UC indicates that bacteria might have a role in pathogenesis or
severity of the disease. The strongest evidence comes from Japanese studies in patients with
moderate to severe colitis, which demonstrated that triple therapy with penicillin ,
tetracycline and metronidazole led to remission in steroid refractory patients in 60% of
patients, and this was reproduced in a follow up randomized controlled trial which showed a
70% remission rate (UEGW Amsterdam 2012, Ohkusa T et al 2005 ). On the other hand a previous
trial had shown 44% response and only (Ohkusa T et al 2010). A recent retrospective study in
Israel showed a 65% response and 50% remission rate in patients with severe refractory
colitis. Thus it is unclear at present if antibiotics are useful only in severe colitis , or
if this reflects heterogeneity among studies.
Diet and antibiotics are the two proven treatments that may alter the microbiota clinically.
Theoretically, controlling the microbiota by diet or antibiotics may allow for control of
the disease without immune suppression , and this has yet to be evaluated.
Based on our previous success in improving remission and decreasing inflammation with a
novel dietary intervention in Crohn's disease, and based on these previously mentioned
studies, we have postulated that a diet could be beneficial for patients with Ulcerative
Colitis. We further hypothesize that patients failing diet might respond to antibiotic
therapy If patients respond to the diet this would have an immediate impact and be the first
evidence for a specific diet that works in UC. If the diet fails and the antibiotics
succeed, this would be the first evidence for the effect of oral antibiotics in mild disease
.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02819635 -
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05960864 -
Chinese Spondyloarthritis Inception Cohort (CESPIC)
|
||
Not yet recruiting |
NCT05316220 -
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT02345733 -
Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis
|
Phase 4 | |
Completed |
NCT02778464 -
Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease
|
||
Completed |
NCT01971814 -
Early Serum Infliximab Levels in Severe Ulcerative Colitis.
|
Phase 1 | |
Completed |
NCT03223012 -
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
|
||
Active, not recruiting |
NCT03456206 -
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
|
||
Completed |
NCT04254783 -
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
|
Phase 1 | |
Completed |
NCT03398148 -
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02087878 -
A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
|
||
Completed |
NCT02065622 -
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03695185 -
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
|
Phase 2 | |
Completed |
NCT02108821 -
Fecal Microbiota Transplantation in Pediatric Patients
|
Phase 1 | |
Terminated |
NCT03758443 -
Efficacy & Safety of TD-1473 in Ulcerative Colitis
|
Phase 2/Phase 3 | |
Completed |
NCT01364896 -
Anal Human Papillomavirus in Inflammatory Bowel Disease Study
|
||
Terminated |
NCT03920254 -
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
|
Phase 2/Phase 3 | |
Recruiting |
NCT01277419 -
German Spondyloarthritis Inception Cohort
|
||
Recruiting |
NCT05377580 -
A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT03609905 -
Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis
|
Phase 1/Phase 2 |